Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
   
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  SWAN Knowledge Base
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  Antibodies
  Mutations
  AlzGene
  Research Models
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Expert Opinion
  Ask the Expert
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Compendia: Mutations: APP Mutations Directory
APP Mutations Table

Updated 6 September 2005

Back to Main APP Directory       View APP Mutations Diagram

by John Hardy, National Institute on Aging, Bethesda, MD, and Richard Crook, MD., Mayo Clinic, Jacksonville, FL.

Disease-associated Intra-A#&946; Mutations (Courtesy of Dominic Walsh)

Mutation Phenotype Age of Onset References
Glu665Asp AD, but may not be pathogenic. 86?  Peacock et al., 1994
Lys/Met670/Asn/Leu (Swedish) AD 52 (44-59)  Mullan et al., 1992
Ala673Thr Normal N/A Peacock et al., 1993
His677Arg AD 55 (55-56) Janssen et al., 2003
D678N FAD 60 Wakutani et al., 2004
Ala692Gly (Flemish) Large dense core plaques linked to CAA. 40-60, but variable.  Kumar-Singh et al., 2002
Hendriks et al., 1992
Cras et al., 1998
Roks et al., 2000
Glu693Gly (Artic) AD, but may not be pathogenic.

Reproduced plasma Aβ40 and 42, high protfibril levels.

58?


N/A

Kamino et al., 1992


Nilsbeth et al., 2001

Glu693Gln (Dutch) HCHWA-D (a stroke syndrome).  Typically ~50, but variable.  Van Broeckhoven et al., 1990
Glu693Lys (Italian) Cerebral hemorrhage. ? Tagliavini et al., 1999 (no abstract available)
Asp694Asn (Iowa) AD or Cerebral hemorrhage. 69 Grabowski et al., 2001
Ala713Thr AD, but may not be pathogenic. 59 Carter et al., 1992
Ala713Val Schizophrenia, probably not pathogenic. ? Jones et al., 1992
Thr714Ile (Austrian) Affects γ-secretase cleavage directly, 11X increase in Aβ42/Aβ40 ratio in vitro. In brain, abundant and predominant nonfibrillar pre-amyloid plaques composed primarily of N-truncated Aβ42 in complete absence of Aβ40.   Kumar-Singh et al., 2000
Thr714Ala (Iranian) AD 52 (40-60)  Pasaler et al., 2002
Val715Met (French) AD 52 (40-60)  Ancolio et al., 1999
Val715Ala (German) AD 47 De Jonghe et al., 2001; Cruts et al., 2003
Ile716Val (Florida) AD 55  Eckman et al., 1997
Ile716Thr AD 55  Terrini et al., 2002
Val717Phe (Indiana) AD 47 (42-52) Murrell et al., 1991
Val717Gly AD 55 (45-62)  Chartier-Harlin et al., 1991
Val717Ile (London) AD 55 (50-60) Goate et al., 1991
Val717Leu CSF tau and A-β consistent with AD; earlier onset than other 717 mutations. 38 Murrell et al., 2000
Leu723Pro (Australian) AD 56 (45-60) Kwok, 2000

Mutations in APP, PS1, and PS2 are also listed in the Alzheimer Disease Mutation Database (ADMD), maintained by Marc Cruts.

Copyright © 1996-2008 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad